ETARACIZUMAB: A DEEP ANALYSIS INTO MEDI523 AND LM609

Etaracizumab, formerly referred to as MEDI523 and subsequently LM609, represents a unique approach in antibody-mediated therapy. This monoclonal protein is designed to precisely inhibit the activity of complement protein , a vital component of the cascade involved in inflammation . Data have foc